Daxor Corporation to Present at Global Investment Conference
Oak Ridge, TN – Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, has announced that its CEO and President, Michael Feldschuh, will be presenting at the 26th Annual Global Investment Conference hosted by H.C. Wainwright. This event is scheduled to take place from September 9 to September 11 at the prestigious Lotte New York Palace Hotel.
Details and Accessibility of the Conference
The presentation will be available for on-demand viewing starting September 9 at 7:00 AM ET. This feature allows interested investors to engage with the content at their own pace, ensuring they can access vital insights regarding Daxor's ongoing advancements in medical technology.
Opportunities for Investor Engagement
During the conference, Mr. Feldschuh will be available for one-on-one meetings with registered investors. This presents an excellent opportunity for investors to gain a deeper understanding of Daxor’s innovative solutions and to ask questions directly.
Contact Information for Investor Relations
Investors interested in scheduling a personal meeting are encouraged to reach out to Bret Shapiro at CORE IR. He can be contacted at 1-516-222-2560 or via email to discuss any inquiries related to Daxor's presentation or company initiatives.
About Daxor Corporation
Daxor Corporation, identified by the ticker Nasdaq: DXR, is at the cutting edge of innovations in blood volume measurement. Its flagship product, the BVA-100™, is the only FDA-cleared test that provides a safe and accurate assessment of blood volume status. This diagnostic tool is essential for enhancing hospital performance by effectively supporting the management of various medical conditions.
Healthcare Impact
To date, over 65,000 BVA-100 tests have been conducted in leading hospitals nationwide, significantly improving care metrics in surgical and critical care environments. Importantly, Daxor’s technology plays a vital role in lowering mortality and readmission rates for patients suffering from heart failure.
Research and Development Efforts
Daxor is actively engaged in several research trials focused on heart failure treatment, supported by the National Institutes of Health (NIH). Additionally, the company is collaborating with the U.S. Department of Defense to develop analyzers that improve care for combat casualties.
Mission and Vision of Daxor
Daxor's mission is straightforward: to transform healthcare through optimal fluid management enabled by blood volume analysis. The company envisions a future where optimal blood volume assessment becomes a standard practice for all patients, leading to better healthcare outcomes globally.
Frequently Asked Questions
What is Daxor Corporation's primary focus?
Daxor Corporation specializes in blood volume measurement technology, emphasizing innovation and improving healthcare outcomes.
When will Daxor’s presentation be available to view?
The presentation will be available for on-demand viewing starting September 9, 2024, at 7:00 AM ET.
How can investors schedule a meeting with Daxor’s CEO?
Investors can schedule a meeting with CEO Michael Feldschuh at the conference by registering and contacting Bret Shapiro at CORE IR.
What is the significance of Daxor's BVA-100™ device?
The BVA-100™ is the only FDA-approved blood volume diagnostic test that provides essential metrics for assessing a patient's blood volume status, fundamentally enhancing patient care.
How many BVA-100 tests have been performed?
More than 65,000 tests have been conducted, demonstrating the widespread acceptance and effectiveness of Daxor’s technology in various medical settings.
